Teleflex Completes Enrollment in CTO-PCI IDE Study
Enrollment Completed Ahead of Schedule in Study Evaluating the Performance of Teleflex Specialty Catheters and Coronary Guidewires in Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Interventions
WAYNE, Pa., Feb. 17, 2021 (GLOBE NEWSWIRE) Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the completion of patient enrollment in a clinical study evaluating the performance of Teleflex specialty catheters and coronary guidewires in Chronic Total Occlusion (CTO) percutaneous coronary intervention (PCI) procedures currently an investigational indication for these products. The study enrolled 150 patients across 13 investigational sites in the US and completed enrollment three months ahead of schedule. The CTO-PCI study is a prospective, single-arm IDE study employing the primary angiographic endpoint of successful (intralumenal) guidewire placement beyond the CTO.
Nasal spray blocks COVID-19 infection in ferrets cornell.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cornell.edu Daily Mail and Mail on Sunday newspapers.
Loading video.
VIDEO: Animation showing how the antiviral lipopeptide prevents coronavirus infection by blocking spike protein-mediated fusion. view more
Credit: Visualization by Gaël McGill, Ph.D. & Jonathan Khao, Ph.D., Harvard Medical School and Digizyme (www.digizyme.com (link is external and opens in a new window)) created with.
A nasal antiviral created by researchers at Columbia University Vagelos College of Physicians and Surgeons blocked transmission of SARS-CoV-2 in ferrets, suggesting the nasal spray also may prevent infection in people exposed to the new coronavirus, including recent variants
The compound in the spray a lipopeptide developed by Matteo Porotto, PhD, and Anne Moscona, MD, professors in the Department of Pediatrics and directors of the Center for Host-Pathogen Interaction is designed to prevent the new coronavirus from entering host cells.
comments
It was the first time the doctor and I had seen each other in a year. This was in December; I was in for my annual scans and blood work. We made small talk, catching up on the various ways 2020 had ravaged us both. I learned she d been caught in the city s first wave of COVID-19 cases, back in March. She d been seriously ill, and her sense of taste and smell were still not back to normal. Then she asked if I d been sick. No, I told her. I d stayed home, and I wasn t in a high risk group. Well, she said, her eyes flicking down on the results of my latest labs, and your blood type.
E-Mail
DALLAS and NEW YORK - February 16, 2021 - The Heart Valve Collaboratory (HVC) announced today that the U.S. Food and Drug Administration (FDA) s Center for Devices and Radiological Health (CDRH) will participate in this collaborative community . A medical collaboratory is a forum in which multidisciplinary private and public sector members work together on medical device challenges to achieve aligned outcomes, solve shared problems, and leverage collective opportunities, in the interest of improving patient care. The FDA s Center for Devices and Radiological Health is committed to fostering innovation while encouraging development of safe and effective technologies for patients, said Bram Zuckerman, M.D., director of the Office of Cardiovascular Devices in the FDA s Center for Devices and Radiological Health. We can continue to protect and promote public health when key stakeholder groups work together. Collaborative communities can contribute to improvements in are